Minimally invasive (laparoscopic) Whipple procedure for pancreatic and periampullary tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective single-center protocol offering complete laparoscopic pancreaticoduodenectomy (resection and reconstruction) to patients with resectable pancreatic head, ampullary, duodenal, or distal bile duct tumors. Eligible patients have no distant metastases and no radiologic involvement of the superior mesenteric or portal veins or major arterial encasement. Surgeons perform the complex laparoscopic dissection and anastomoses and record perioperative, surgical and early oncologic outcomes, including complications such as pancreatic fistula. The aim is to document safety, operative feasibility, and short-term morbidity in a center experienced with hepatobiliary surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients meeting the curative treatment intent in accordance with clinical guidelines:

  * No evidence of metastasis.
  * Radiological non-involvement of superior mesenteric vein \& portal vein.
  * Preserved fat planes between celiac axis, hepatic artery \& superior mesenteric artery.
* Patients presenting with resectable pancreatic head cancer, cholangiocarcinoma, duodenal cancer and ampullary tumours who are fit for laparoscopic pancreaticoduodenectomy.

Exclusion Criteria:

* Unfit patients for surgery due to severe medical illness.
* Inoperable patients with distant metastases, including peritoneal, liver, distant lymph node metastases, and involvement of other organs.
* Irresectable tumors in diagnostic laparoscopy.
* Patients requiring left, central or total pancreatectomy or other palliative surgery.
* History of other malignant disease.
* Pregnant or breast-feeding women.
* Patients with serious mental disorders.
* Patients with vascular invasion and requiring vascular resection as evaluated by the multidisciplinary team team according to abdominal imaging data.
* Pancreatoduodenectomy for other diagnosis like cystic lesions, benign tumors or chronic calcific pancreatitis
* Patients with cirrhotic liver.
* Patients refused to participate in the study.

Where it's running

• Liver and GIT hospital , Minia University
  Minya, Egypt Recruiting

Study contacts

• Principal investigator: Saleh K Saleh, MD — Minia University
• Study coordinator: Saleh K Saleh, MD
• Email: salehkhairy@mu.edu.eg
• Phone: 01201765401

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tissue adhesive (Glubran®2) to reinforce pancreaticojejunostomy in soft pancreas

  This trial will test whether adding a tissue adhesive glue (Glubran®2) to the pancreatic-jejunal connection reduces postoperative pancreatic leaks in adults with a soft pancreas undergoing pancreaticoduodenectomy.

  Recruiting Minia University · Minya, Minya Governorate · NCT07155525

• Predicting pancreatic fistula after pancreaticoduodenectomy

  This project will try to find which before-, during-, and after-surgery factors predict clinically significant pancreatic fistula in adults having pancreaticoduodenectomy for pancreatic or periampullary tumors.

  Recruiting Minia University · Minya · NCT07022015

• Analyzing factors affecting pancreatic tumors and cysts

  This study looks at how different factors affect pancreatic tumors and cysts to help improve treatment options for patients.

  Recruiting Umeå University · Umeå · NCT05155878

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer

  This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07895498

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.